GLPwatch

Effective oral delivery of Exenatide-Zn<sup>2+</sup> complex through distal ileum-targeted double layers nanocarriers modified with deoxycholic acid and glycocholic acid in diabetes therapy.

Biomaterials · 2021

Last updated 2026-05-28

Researchers developed a new nanoparticle designed to deliver the diabetes drug Exenatide orally, rather than by injection. In animal studies, this nanoparticle targeted the lower small intestine, increased Exenatide levels in the blood, and improved blood sugar control for a longer time while also lowering blood fat levels and reducing damage to organs. The nanoparticle was made of two bile acid components and measured 140 nanometers in size.

AI summary of the abstract below.

JournalBiomaterials, 2021
Citations29
Relative citation ratio1.97
NIH percentile73
Molecules exenatide
Conditions studied Type 2 Diabetes

Abstract

The oral administration route is popular with T2DM patients because they need convenience in lifelong medication. At present, oral Exenatide is not available on the market and therefore the relevant studies are valuable. Herein, we constructed a novel dual cholic acid-functionalized nanoparticle for oral delivery of Exenatide, which was based on the functionalized materials of deoxycholic acid-low molecular weight protamine and glycocholic acid-poly (ethylene glycol)-b-polysialic acid. The hydrophobic deoxycholic acid strengthened the nanoparticles and the hydrophilic glycolic acid targeted to specific transporter. We first condensed Exenatide-Zn complex with deoxycholic acid-low molecular weight protamine to prepare nanocomplexes with ζ-potentials of +8 mV and sizes of 95 nm. Then, we used glycocholic acid-poly (ethylene glycol)-b-polysialic acid copolymers masking the positive charge of nanocomplexes to prepare nanoparticles with negative charges of -22 mV and homogeneous sizes of 140 nm. As a result, this dual cholic acid-functionalized nanoparticle demonstrated enhanced uptake and transport of Exenatide, and a special targeting to apical sodium-dependent cholic acid transporter in vitro. Moreover, in vivo studies showed that the nanoparticle effectively accumulated in distal ileum, raised the plasma concentration of Exenatide, prolonged hypoglycemic effect, reduced blood lipid levels, and lightened organ lesions.

Verbatim abstract via PubMed 34153783 ↗

Related research